HUTCHMED's Sovleplenib Achieves Positive Phase III Results for wAIHA, NDA Submission Planned
HCM sits 25% above its 52-week low of $11.505.
Summary
HUTCHMED reported positive Phase III clinical trial results for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) in China, with plans to submit a New Drug Application (NDA) in the first half of 2026.
Key Events · Product Development and Regulatory · HCM
-
Positive Phase III Trial Results
Sovleplenib met its primary endpoint in the ESLIM-02 Phase III trial for warm antibody autoimmune hemolytic anemia (wAIHA) in China, demonstrating rapid and durable hemoglobin responses.
-
Regulatory Submission Planned
HUTCHMED plans to submit a New Drug Application (NDA) for sovleplenib for wAIHA to the China National Medical Products Administration (NMPA) in the first half of 2026.
-
Addresses Serious Condition
wAIHA is the most common form of autoimmune hemolytic anemia, a potentially life-threatening autoimmune disorder characterized by red blood cell destruction, with limited treatment options.
-
Broader Pipeline Potential
Sovleplenib is also being studied in immune thrombocytopenia (ITP), with an NDA resubmission for second-line ITP planned in the first half of 2026.
Analysis · HCM · Life Sciences
HUTCHMED announced positive topline results from its Phase III ESLIM-02 trial for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) in China. Meeting the primary endpoint in a Phase III study significantly de-risks this novel spleen tyrosine kinase (Syk) inhibitor, paving the way for a New Drug Application (NDA) submission to the China NMPA in the first half of 2026. This development is crucial as wAIHA is a serious, potentially life-threatening autoimmune disorder with unmet medical needs. The success of sovleplenib in this indication, alongside its ongoing development for immune thrombocytopenia (ITP), strengthens HUTCHMED's pipeline and future revenue potential in the life sciences sector.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $14.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $11.51 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.